Drug Profile
Research programme: membrane-bound stem cell factor gene therapy - Eiger BioPharmaceuticals Inc
Alternative Names: mSCF - Celladon; mSCF gene therapy - CelladonLatest Information Update: 28 Jan 2020
Price :
$50
*
At a glance
- Originator Icahn School of Medicine at Mount Sinai
- Developer Celladon; Icahn School of Medicine at Mount Sinai
- Class Cytokines; Gene therapies
- Mechanism of Action Gene transference; Proto-oncogene protein c-kit expression stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Suspended Ischaemic heart disorders; Myocardial infarction
Most Recent Events
- 07 Aug 2015 Research programme: membrane-bound stem cell factor gene therapy - Celladon is available for licensing as of 26 Jun 2015. www.celladon.com
- 26 Jun 2015 Suspended - Preclinical for Ischaemic heart disorders in USA (unspecified route)
- 26 Jun 2015 Suspended - Preclinical for Myocardial infarction in USA (unspecified route)